Serum metabolomics reveals personalized metabolic patterns for macular neovascular patient stratification.
Macular neovascular disease is a group disorder with complex pathogenesis of neovascularization for vision impairment and irreversible blindness, posing great challenges to precise diagnosis and management. We prospectively recruited participants with age-related macular degeneration (AMD), polypoidal choroidal vasculopathy (PCV) and pathological myopia (PM), compared with cataract patients without fundus diseases as control group. The serum metabolome was profiled by gas chromatography coupled with time-of-flight mass spectrometry (GC-TOFMS) analysis. Multivariate statistical methods as well as data mining were performed for interpretation of macular neovascularization. A total of 446 participants with macular neovascularization and 138 cataract subjects as control group were enrolled in this study. By employing GC-TOFMS, 131 metabolites were identified and 33 differentiating metabolites were highlighted in patients with macular neovascularization. For differential diagnosis, 3 panels of specific metabolomics-based biomarkers provided areas under the curve of 0.967, 0.938 and 0.877 in the discovery phase (n= 328), predictive values of 87.3%, 79% and 85.7% in the test phase (n= 256). Personalized pathway dysregulation scores measurement using lilikoi package in R language revealed pentose phosphate pathway and mitochondrial electron transport chain as the most important pathways in AMD; purine metabolism and glycolysis were identified as the major disturbed pathways in PCV while the altered thiamine metabolism and purine metabolism may contribute to PM phenotypes. Serum metabolomics are powerful for characterizing metabolic disturbances of macular neovascular. Differences in metabolic pathways may reflect underlying macular neovascularand serve as therapeutic targets for macular neovascular treatment.